News
-
-
-
COMMUNIQUÉ DE PRESSE
VeonGen Announces Clinical Progress of VG801 Gene Therapy in Stargardt Disease, with an Oral Presentation at ARVO 2026
VeonGen announces positive clinical progress of VG801 gene therapy for Stargardt Disease, including FDA and RMAT support, with promising efficacy and safety profile. Presentation at ARVO 2026 -
-
-
COMMUNIQUÉ DE PRESSE
VeonGen Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for VG801 Gene Therapy for Stargardt Disease
VeonGen Therapeutics receives FDA RMAT designation for VG801 gene therapy targeting Stargardt Disease, a milestone in genetic medicine development -
-
-
COMMUNIQUÉ DE PRESSE
ViGeneron Rebrands as VeonGen Therapeutics and Announces FDA Rare Pediatric Disease Designation and Clinical Progress for Lead Gene Therapy VG801 in Stargardt Disease
VeonGen Therapeutics (formerly ViGeneron) announces FDA Rare Pediatric Disease Designation and clinical progress for lead gene therapy VG801 in Stargardt Disease, advancing genetic medicine in ophthalmology and beyond
